The Combination of Rifampin plus Moxifloxacin Is Synergistic for Suppression of Resistance but Antagonistic for Cell Kill of Mycobacterium tuberculosis as Determined in a Hollow-Fiber Infection Model

Moxifloxacin is under development for expanded use against Mycobacterium tuberculosis. Rifampin is a mainstay of therapy. We examined the interaction of moxifloxacin plus rifampin for log-phase and nonreplicating persister (NRP) organisms. For this evaluation, we employed our hollow-fiber infection...

Descripción completa

Detalles Bibliográficos
Autores principales: Drusano, G. L., Sgambati, Nicole, Eichas, Adam, Brown, David L., Kulawy, Robert, Louie, Arnold
Formato: Texto
Lenguaje:English
Publicado: American Society of Microbiology 2010
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2925073/
https://www.ncbi.nlm.nih.gov/pubmed/20802826
http://dx.doi.org/10.1128/mBio.00139-10

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2925073/
https://www.ncbi.nlm.nih.gov/pubmed/20802826
http://dx.doi.org/10.1128/mBio.00139-10

Ejemplares similares